Nektar Therapeutics provided earnings guidance for the year 2023. The company's GAAP revenue for full year 2023 is expected to be between $80 million and $90 million. This revenue includes $65 million to $70 million in noncash royalties and $15 million to $20 million in product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | -2.56% | -11.63% | +101.77% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+101.77% | 210M | |
+52.93% | 803B | |
+40.98% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 244B | |
+2.17% | 226B | |
+10.66% | 215B | |
+6.24% | 164B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Earnings Guidance for the Year 2023